AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $35.11.

Several brokerages recently weighed in on ANAB. HC Wainwright reaffirmed a "neutral" rating and set a $22.00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Wedbush reiterated an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research note on Wednesday, February 12th. Guggenheim restated a "buy" rating on shares of AnaptysBio in a research report on Monday, March 3rd. BTIG Research cut AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. Finally, Wells Fargo & Company lifted their price target on AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th.

AnaptysBio Trading Down 1.4 %

Shares of NASDAQ ANAB traded down $0.27 during trading hours on Friday, reaching $18.44. The stock had a trading volume of 1,206,474 shares, compared to its average volume of 546,039. The firm has a market cap of $565.50 million, a price-to-earnings ratio of -3.03 and a beta of 0.02. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The firm has a 50-day moving average of $16.88 and a 200-day moving average of $22.34.

Remove Ads

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The business had revenue of $43.11 million for the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, equities analysts predict that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has approved a share buyback plan on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc purchased 6,646 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company's stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 33.70% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

A number of large investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock worth $110,857,000 after acquiring an additional 438,557 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company's stock valued at $74,008,000 after purchasing an additional 43,598 shares in the last quarter. Vanguard Group Inc. raised its position in AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after purchasing an additional 143,584 shares during the period. Fairmount Funds Management LLC acquired a new position in shares of AnaptysBio during the fourth quarter worth $24,050,000. Finally, Boxer Capital Management LLC acquired a new stake in shares of AnaptysBio during the fourth quarter valued at about $17,212,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.